SELLAS Life Sciences Group, Inc. (SLS)
13.86
+0.16
(+1.17%)
USD |
NASDAQ |
Sep 04, 16:00
13.90
+0.04
(+0.29%)
After-Hours: 20:00
SELLAS Life Sciences Group Research and Development Expense (Quarterly) : 6.272M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.272M |
| March 31, 2026 | 5.129M |
| December 31, 2025 | 4.73M |
| September 30, 2025 | 4.216M |
| June 30, 2025 | 3.871M |
| March 31, 2025 | 3.205M |
| December 31, 2024 | 4.437M |
| September 30, 2024 | 4.362M |
| June 30, 2024 | 5.186M |
| March 31, 2024 | 5.111M |
| December 31, 2023 | 5.097M |
| September 30, 2023 | 5.813M |
| June 30, 2023 | 5.923M |
| March 31, 2023 | 7.174M |
| December 31, 2022 | 5.846M |
| September 30, 2022 | 4.282M |
| June 30, 2022 | 5.529M |
| March 31, 2022 | 4.611M |
| December 31, 2021 | 3.393M |
| September 30, 2021 | 4.541M |
| June 30, 2021 | 3.456M |
| March 31, 2021 | 4.284M |
| December 31, 2020 | 2.771M |
| September 30, 2020 | 2.367M |
| June 30, 2020 | 2.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.864M |
| December 31, 2019 | 2.246M |
| September 30, 2019 | 1.799M |
| June 30, 2019 | 1.381M |
| March 31, 2019 | 1.859M |
| December 31, 2018 | 3.651M |
| September 30, 2018 | 1.72M |
| June 30, 2018 | 1.592M |
| March 31, 2018 | 1.804M |
| December 31, 2017 | 0.71M |
| September 30, 2017 | 1.068M |
| June 30, 2017 | 1.827M |
| March 31, 2017 | 2.184M |
| December 31, 2016 | 4.618M |
| September 30, 2016 | 3.624M |
| June 30, 2016 | 6.175M |
| March 31, 2016 | 5.443M |
| December 31, 2015 | 4.849M |
| September 30, 2015 | 5.74M |
| June 30, 2015 | 7.29M |
| March 31, 2015 | 5.91M |
| December 31, 2014 | 6.272M |
| September 30, 2014 | 7.243M |
| June 30, 2014 | 8.069M |
| March 31, 2014 | 6.77M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Lite Strategy, Inc. | 0.03M |
| AbbVie, Inc. | 2.344B |
| Marker Therapeutics, Inc. | 1.476M |
| TG Therapeutics, Inc. | 95.34M |
| Rezolute, Inc. | 11.41M |